Outcomes
SECONDARY, INSULIN SENSITIVITY
The primary objective of this study was to demonstrate the superiority of beinaglutide versus aspart 30 in reducing blood glucose and the low blood glucose index (LBGI) levels after 6 months. At the same time, the incidence of ADAs was used to assess the safety of beinaglutide. The secondary efficacy endpoints were lipid profile, especially non-fasting TG levels. Other endpoints were weight, waist circumference (WC), BMI, subcutaneous fat, and insulin sensitivity index (HOMA-IR).